WHAT IS ZOFRAN®?
Zofran® (ondansetron and ondansetron hydrochloride) was approved by the FDA in 1991 to treat nausea associated with chemotherapy and surgery. Since that time, Zofran® has been widely used “off label” to treat nausea that comes with pregnancy. Zofran® has never been approved by the FDA to treat nausea associated with pregnancy and Zofran® has never been proven safe for unborn children. To the contrary, there is substantial scientific evidence to suggest that Zofran® can cause heart defects, cleft lip and cleft palate, and other birth defects.
JUST A LITTLE “OFF LABEL” MARKETING?
The off label use of Zofran® to treat nausea in pregnant women didn’t happen accidentally. GlaxoSmithKline paid about $3 billion to settle criminal charges arising out of the off label marketing of Zofran and other illegal marketing activities. Make your own conclusions about this company after reading this. Glaxo’s Settlement With The Government. The Department of Justice called it the “Largest Health Care Fraud Settlement In U.S. History.” Glaxo To Plead Guilty And Pay $3 Billion.
STATUS OF THE LITIGATION AGAINST THE MANUFACTURER OF ZOFRAN
The federal court system has centralized the Zofran® litigation in the United States District Court for the District Of Massachusetts. As of May, 2016, that court presided over more than 200 individual Zofran lawsuits. The litigation is in its infancy. There have been no Zofran® trials or reports of mass settlements.
OUR INVOLVEMENT IN THE LITIGATION
We currently represent about 30 families from across the country in Zofran® cases. If you took Zofran® or its generic, ondansetron during the first trimester of your pregnancy and your child was born with a birth defect, take the first step to protect your child’s rights by calling us for a free consultation from an experienced lawyer. Our toll free number is (877) 704-7674. These are serious cases and they deserve individual attention. Our clients owe us nothing for the investigation or prosecution of their case unless we obtain a recovery for them.